Global Respiratory Partnering 2012-2018: Deal trends, players and financials

Global Respiratory Partnering 2012 to 2018 provides the full collection of Respiratory disease deals signed between the worlds pharmaceutical and biotechnology companies since 2012.

Trends in Respiratory partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Respiratory partnering agreement structure
Respiratory partnering contract documents
Top Respiratory deals by value
Most active Respiratory dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensors product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Respiratory dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Respiratory deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Respiratory deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2012. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.

Report scope

Global Respiratory Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Respiratory trends and structure of deals entered into by leading companies worldwide.

Global Respiratory Partnering 2012 to 2018 includes:

Trends in Respiratory dealmaking in the biopharma industry since 2012
Analysis of Respiratory deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Respiratory deal contract documents
Comprehensive access to over 3500 Respiratory deal records
The leading Respiratory deals by value since 2012
Most active Respiratory dealmakers since 2012

The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.

In GlobalRespiratory Partnering 2012 to 2018, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Respiratory Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 400 respiratory deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Respiratory dealmaking

2.1. Introduction
2.2. Respiratory partnering over the years
2.3. Respiratory partnering by deal type
2.4. Respiratory partnering by industry sector
2.5. Respiratory partnering by stage of development
2.6. Respiratory partnering by technology type
2.7. Respiratory partnering by therapeutic indication

Chapter 3 Financial deal terms for Respiratory partnering

3.1. Introduction
3.2. Disclosed financials terms for Respiratory partnering
3.3. Respiratory partnering headline values
3.4. Respiratory deal upfront payments
3.5. Respiratory deal milestone payments
3.6. Respiratory royalty rates

Chapter 4 Leading Respiratory deals and dealmakers

4.1. Introduction
4.2. Most active in Respiratory partnering
4.3. List of most active dealmakers in Respiratory
4.4. Top Respiratory deals by value

Chapter 5 Respiratory contract document directory

5.1. Introduction
5.2. Respiratory partnering deals where contract document available

Chapter 6 Respiratory dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Respiratory therapeutic target

Appendices

Appendix 1 Directory of Respiratory deals by company A-Z 2012 to 2018
Appendix 2 Directory of Respiratory deals by deal type 2012 to 2018
Appendix 3 Directory of Respiratory deals by stage of development 2012 to 2018
Appendix 4 Directory of Respiratory deals by technology type 2012 to 2018
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures

Figure 1: Respiratory partnering since 2012
Figure 2: Respiratory partnering by deal type since 2012
Figure 3: Respiratory partnering by industry sector since 2012
Figure 4: Respiratory partnering by stage of development since 2012
Figure 5: Respiratory partnering by technology type since 2012
Figure 6: Respiratory partnering by indication since 2012
Figure 7: Respiratory deals with a headline value
Figure 8: Respiratory deals with upfront payment values
Figure 9: Respiratory deals with milestone payment
Figure 10: Respiratory deals with royalty rates
Figure 11: Active Respiratory dealmaking activity 2012 to 2018
Figure 12: Top Respiratory deals by value since 2012

Global Enteric Diseases: Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio, Yersinia--Supplier Shares, Market Segment Forecasts, Competitive Strategies, Technology and Instrumentation Review, Emerging Opportunities

About this ReportThis new 389-page report presents detailed analysis of the Enteric Disease market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.  Current scientific views on epidemiology

USD 8500 View Report

Global Respiratory Diseases: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Country Shares, Market Segment Forecasts, Competitive Strategies, Technology and Instrumentation Review, Opportunities for Suppliers

About this ReportThis new 366-page report presents detailed analysis of the Respiratory Disease market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.  Current scientific views on epidemiology

USD 8500 View Report

Global Respiratory Diseases: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Country Shares, Market Segment Forecasts, Competitive Strategies, Technology and Instrumentation Review, Opportunities for Suppliers

About this ReportThis new 366-page report presents detailed analysis of the Respiratory Disease market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.  Current scientific views on epidemiology

USD 8500 View Report

Global Respiratory Drug Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Respiratory Drug is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available